Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.

Publikation

Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents.

Wissenschaftlicher Artikel/Review - 22.07.2024

Jörger Markus, Koster Kira-Lee, Janik Tomas, de Jong Floris A

Zitation

Jörger M, Koster K, Janik T, de Jong F. Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents. Cancer Manag Res 2024; 16:855-869.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Cancer Manag Res 2024; 16

Veröffentlichungsdatum

22.07.2024

ISSN (Druck)

1179-1322

Seiten

855-869

Kurzbeschreibung/Zielsetzung

Immune checkpoint inhibitors (CPIs) have been widely adopted in a number of early and advanced malignancies. Histone deacetylase inhibitors (HDACis) and alkylating agents (AAs) have been suggested to potentiate the actions of CPIs on tumor cells. We conducted a comprehensive literature review to explore the potential synergistic activity between CPIs, AAs, and HDACis.